Dr. Vijay Krishna Sandilya, MD

Dr. Sandilya practices at Shore Medical Center in Somers Point, New Jersey, part of Shore Medical Center.

Dr. Sandilya's NPI, 1801118906, was assigned on February 17, 2010. Dr. Sandilya holds Pennsylvania license MD439106.

Dr. Sandilya's primary practice is Shore Medical Center, at 100 Medical Center Way, Somers Point, NJ 08244 in Atlantic County. The practice phone is (609) 653-3500.

Dr. Sandilya's primary practice is Shore Medical Center in Somers Point, New Jersey, part of Shore Medical Center. Dr. Sandilya is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Shore Medical Center. Dmand AI also links Dr. Sandilya to 3 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sandilya practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sandilya's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sandilya is licensed in Pennsylvania.

CMS data shows 1,695 Medicare services from Dr. Sandilya across 11 procedure codes in 2024, for 570 Medicare patients. Medicare paid $129,344 for them.

CMS counts 570 Medicare patients who saw Dr. Sandilya in 2024. The largest group is 65 to 74, with 242 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sandilya's median patient age at 69, with 56% women.

In 2024, Dr. Sandilya wrote 465 Medicare Part D claims for 152 patients. 73% of them were for generic drugs. CMS names the drug for 252 of them, across 9 drugs with 11 or more claims each, at $950,426 in total drug cost. In 2023, CMS named 365 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Sandilya for performance year 2024, reported as part of a group. Dr. Sandilya accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Sandilya in 2018. The most frequent topics are Antibodies, Bacterial, Pneumococcal Vaccines and Polysaccharides, Bacterial.

Dmand AI links Dr. Sandilya to 5 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Triple Negative Breast Neoplasms and Carcinoma, Intraductal, Noninfiltrating. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 955 general payments to Dr. Sandilya from 91 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. Leadiant Biosciences, Inc. paid the most, $3,295.